Affimed N.V. (AFMD) Q2 2019 Earnings Conference Call August 7, 2019 08:30 ET Company Participants Greg Gin - Head of IR Adi Hoess - CEO Leila Alland - Chief Medical Officer Michael Wolf - Head, Finance Conference Call Participants Maury Raycroft - Jefferies Daina Graybo...

Affimed (NASDAQ: AFMD ): Q2 GAAP EPS of -€0.17  misses by €0.03 . More news on: Affimed N.V., Earnings news and commentary, Healthcare stocks news, , Read more ...

Heidelberg, Germany, August 7, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today reported financial and operating results for the second quarter ended June 30, 2019. “A...